Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short-term Investments (2016 - 2025)

Standard Biotools (LAB) has disclosed Short-term Investments for 13 consecutive years, with $65.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments fell 57.94% to $65.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $65.5 million, a 57.94% decrease, with the full-year FY2024 number at $126.1 million, up 99.63% from a year prior.
  • Short-term Investments was $65.5 million for Q3 2025 at Standard Biotools, down from $78.5 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $175.2 million in Q1 2024 to a low of $40.9 million in Q1 2023.
  • A 4-year average of $102.5 million and a median of $107.2 million in 2025 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: plummeted 60.63% in 2023, then soared 328.7% in 2024.
  • Standard Biotools' Short-term Investments stood at $84.5 million in 2022, then fell by 25.2% to $63.2 million in 2023, then skyrocketed by 99.63% to $126.1 million in 2024, then plummeted by 48.09% to $65.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Short-term Investments are $65.5 million (Q3 2025), $78.5 million (Q2 2025), and $107.2 million (Q1 2025).